Skip navigation
Watchlist Sponsored By :


Current DateTime: 09:46:09 16 Nov 2009
LinksList Documentid: 24355697

FEATURED QUIZZES


Current DateTime: 09:46:09 16 Nov 2009
LinksList Documentid: 33793611
  • How Much Do You Know About Green?

      Green has become part of our everyday lives. Green is everywhere-- energy, clothing, food, housing, transportation. It's a big business and a global business.

  • The Billionaire BFF's

      Philanthropists. Bridge partners. Hockey players. Which responses are based on facts from Buffett's and Gates' real lives?

  • The Many Myths of Coca-Cola

      Can you tell which statements are true, and which ones are just rumors?


Current DateTime: 09:46:09 16 Nov 2009
LinksList Documentid: 24890560
  • Winterizing Your Portfolio

      If 2009 was the winter of our discontent, will 2010 be a winter wonderland for investors? A lot depends on the recovery—or lack thereof.

  • Investor's Guide to Real Estate

      Some even say the long-awaited recovery is here. Regardless, buyers and sellers alike can profit from our guide.

  • Alternative Investing

      Stocks and bonds? Sure. But it's a big world out there for investors.

powered by digg
Johnson & Johnson Arthritis Drug Gets FDA Approval
By: AP | 24 Apr 2009 | 05:41 PM ET
Text Size

The Food and Drug Administration on Friday approved a potential blockbuster drug from Johnson & Johnson that fights three forms of arthritis caused by immune-system disorders.
CNBC.com

The injectable medication called Simponi is essentially a follow-up to the multibillion-dollar drug Remicade, which is marketed in the U.S. by J&J and in Europe and other countries by Schering-Plough. Combined sales of the drug were over $5 billion last year.

Sales of the new drug would be similarly split between the two companies.

FDA regulators have approved the drug for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis, a painful, progressive form of spinal arthritis. All three forms of arthritis are chronic disorders in which the immune system attacks joints, causing stiffness, pain and restricted motion.

The drug is injected under the skin once a month and is designed to be used alongside immune-system supressing drugs.

J&J [JNJ  Loading...      ()   ] and Schering have touted the drug as the new standard of so-called tumor necrosis factor blockers, a group of drugs that includes Wyeth [WYE  Loading...      ()   ] and Amgen's [AMGN  Loading...      ()   ] Enbrel and Abbott Laboratories' Humira. Unlike Simponi, those drugs are generally injected once every week or two weeks.

The drug class works by targeting and neutralizing a protein that, when overproduced, causes inflammation and damage to bones, cartilage and other tissue.

The moneymaking potential of Simponi and Remicade are among the reasons Merck, of Whitehouse Station, N.J., is acquiring Schering-Plough for $41.1 billion.

Merck [MRK  Loading...      ()   ] has structured its purchase of Kenilworth, N.J.-based Schering-Plough [SGP  Loading...      ()   ] as a reverse merger in hopes of avoiding change-of-control provisions in Schering's deal with J&J. Under those rules, marketing rights of Remicade would revert to J&J, wiping out the roughly $2 billion in profits that Schering makes from Remicade each year.

Simponi, known generically as golimumab, was discovered and developed by J&J's Centocor Ortho Biotech unit.

Shares of J&J fell 48 cents Friday to close at $50.92.

© 2009 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
Tools:
Print EmailAdd This share icon
  • digg share

CNBC HIGHLIGHTS

  • CNBC's Jim Goldman asks: Has the sun begun to set on Twitter? Data suggests its best days are over.
  • Everyone wanted a piece of Madoff's "Bullship"--the famous buoy sold for $7,500 at auction. You won't believe these prices.
  • De Loach Vineyards is selling its pinot noir the old fashioned way, helping to cut energy and transportation costs.
  • Why are the Chinese concerned about the progress of U.S. health care legislation?
  • Snoop Dogg
  • CNBC's Maria Bartiromo talks to rapper Snoop Dogg about brand identity in both business and music.
ADD COMMENTS
Remaining characters


Current DateTime: 01:12:16 16 Nov 2009
LinksList Documentid: 29778428

Current DateTime: 10:28:53 16 Nov 2009
LinksList Documentid: 29779196

Current DateTime: 07:02:14 16 Nov 2009
LinksList Documentid: 29779199

Current DateTime: 10:42:55 16 Nov 2009
LinksList Documentid: 29779198
  Data is a real-time snapshot  *Data is delayed at least 15 minutes
Global Business and Financial News, Stock Quotes, and Market Data and Analysis

© 2009 CNBC, Inc.  All Rights Reserved.
A Division of NBC Universal
Thomson ReutersThomson Reuters